vs
Side-by-side financial comparison of Citi Trends Inc (CTRN) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $197.1M, roughly 1.5× Citi Trends Inc). Bio-Techne runs the higher net margin — 12.8% vs -3.5%, a 16.3% gap on every dollar of revenue. On growth, Citi Trends Inc posted the faster year-over-year revenue change (10.1% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -4.3%).
Citi Trends, Inc. is an American retail clothing chain selling discounted products targeted primarily at African-American customers.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
CTRN vs TECH — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $197.1M | $295.9M |
| Net Profit | $-6.9M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | -3.7% | 18.4% |
| Net Margin | -3.5% | 12.8% |
| Revenue YoY | 10.1% | -6.4% |
| Net Profit YoY | 3.6% | 68.3% |
| EPS (diluted) | $-0.86 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $197.1M | $295.9M | ||
| Q3 25 | $190.8M | — | ||
| Q2 25 | $201.7M | $317.0M | ||
| Q1 25 | $211.2M | $316.2M | ||
| Q4 24 | $179.1M | $297.0M | ||
| Q3 24 | $176.6M | $289.5M | ||
| Q2 24 | $186.3M | $306.1M | ||
| Q1 24 | $215.2M | $303.4M |
| Q4 25 | $-6.9M | $38.0M | ||
| Q3 25 | $3.8M | — | ||
| Q2 25 | $871.0K | $-17.7M | ||
| Q1 25 | $-14.2M | $22.6M | ||
| Q4 24 | $-7.2M | $34.9M | ||
| Q3 24 | $-18.4M | $33.6M | ||
| Q2 24 | $-3.4M | $40.6M | ||
| Q1 24 | $3.6M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | -3.7% | 18.4% | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 0.2% | -7.5% | ||
| Q1 25 | 0.6% | 12.2% | ||
| Q4 24 | -4.9% | 16.0% | ||
| Q3 24 | -14.1% | 13.8% | ||
| Q2 24 | -3.7% | 15.0% | ||
| Q1 24 | 1.8% | 22.1% |
| Q4 25 | -3.5% | 12.8% | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 0.4% | -5.6% | ||
| Q1 25 | -6.7% | 7.1% | ||
| Q4 24 | -4.0% | 11.7% | ||
| Q3 24 | -10.4% | 11.6% | ||
| Q2 24 | -1.8% | 13.3% | ||
| Q1 24 | 1.7% | 16.2% |
| Q4 25 | $-0.86 | $0.24 | ||
| Q3 25 | $0.46 | — | ||
| Q2 25 | $0.11 | $-0.11 | ||
| Q1 25 | $-1.70 | $0.14 | ||
| Q4 24 | $-0.86 | $0.22 | ||
| Q3 24 | $-2.21 | $0.21 | ||
| Q2 24 | $-0.42 | $0.26 | ||
| Q1 24 | $0.43 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $107.8M | $2.0B |
| Total Assets | $464.3M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M | ||
| Q1 24 | — | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $107.8M | $2.0B | ||
| Q3 25 | $113.2M | — | ||
| Q2 25 | $108.6M | $1.9B | ||
| Q1 25 | $113.2M | $2.0B | ||
| Q4 24 | $130.3M | $2.1B | ||
| Q3 24 | $136.6M | $2.1B | ||
| Q2 24 | $154.8M | $2.1B | ||
| Q1 24 | $157.7M | $2.0B |
| Q4 25 | $464.3M | $2.5B | ||
| Q3 25 | $457.4M | — | ||
| Q2 25 | $437.4M | $2.6B | ||
| Q1 25 | $462.8M | $2.6B | ||
| Q4 24 | $467.1M | $2.7B | ||
| Q3 24 | $506.7M | $2.7B | ||
| Q2 24 | $484.1M | $2.7B | ||
| Q1 24 | $518.7M | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.6M | — |
| Free Cash FlowOCF − Capex | $767.0K | — |
| FCF MarginFCF / Revenue | 0.4% | — |
| Capex IntensityCapex / Revenue | 4.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $11.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.6M | — | ||
| Q3 25 | $3.9M | — | ||
| Q2 25 | $-11.0M | $98.2M | ||
| Q1 25 | $28.5M | $41.1M | ||
| Q4 24 | $-18.4M | $84.3M | ||
| Q3 24 | $5.6M | $63.9M | ||
| Q2 24 | $-19.6M | $75.5M | ||
| Q1 24 | $23.3M | $81.0M |
| Q4 25 | $767.0K | — | ||
| Q3 25 | $-1.7M | — | ||
| Q2 25 | $-13.1M | $93.3M | ||
| Q1 25 | $26.0M | $31.0M | ||
| Q4 24 | $-20.4M | $77.5M | ||
| Q3 24 | $1.7M | $54.7M | ||
| Q2 24 | $-21.2M | $57.5M | ||
| Q1 24 | $20.0M | $64.5M |
| Q4 25 | 0.4% | — | ||
| Q3 25 | -0.9% | — | ||
| Q2 25 | -6.5% | 29.4% | ||
| Q1 25 | 12.3% | 9.8% | ||
| Q4 24 | -11.4% | 26.1% | ||
| Q3 24 | 0.9% | 18.9% | ||
| Q2 24 | -11.4% | 18.8% | ||
| Q1 24 | 9.3% | 21.3% |
| Q4 25 | 4.0% | — | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 1.0% | 1.5% | ||
| Q1 25 | 1.2% | 3.2% | ||
| Q4 24 | 1.1% | 2.3% | ||
| Q3 24 | 2.2% | 3.2% | ||
| Q2 24 | 0.9% | 5.9% | ||
| Q1 24 | 1.5% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | 1.01× | — | ||
| Q2 25 | -12.59× | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | 6.56× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTRN
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
